文献速递神经肿瘤

组织学诊断为WHO II或III级星形细胞瘤的IDH1/2野生型CNS WHO 4级胶质瘤的治疗结局

Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas.
PubMed 文献 · J Neurooncol · 2024-02-07

本研究回顾性分析2016至2019年六家神经外科中心收治的157例组织学诊断为WHO 2-3级IDH1/2野生型星形细胞瘤患者,评估无进展生存期和总生存期及预后因素。结果显示中位PFS为12.5个月、中位OS为27.0个月,WHO分级间无差异;全切除和次全切除较活检显著延长PFS和OS;Stupp方案未较长于单独化疗或放疗;EGFR扩增和TERT启动子突变与OS缩短相关。

要点

  • IDH1/2野生型星形细胞瘤组织学WHO 2-3级中位PFS 12.5个月、OS 27.0个月,WHO分级间无差异。
  • 全切除和次全切除较活检显著延长PFS(P<0.01)和OS(P<0.001)。
  • Stupp方案未较长于单独化疗或放疗的OS或PFS;EGFR扩增(P=0.014)和TERT启动子突变(P=0.042)与OS缩短相关。

核心结论

  • 组织学WHO 2级和3级IDH1/2野生型星形细胞瘤按相同治疗协议治疗,总生存期相似;年龄、切除程度和强EGFR表达是最重要的治疗相关预后因素。

研究设计与样本

  • 多中心回顾性研究,纳入2016至2019年间在六家神经外科科室接受手术、组织学诊断为WHO 2-3级IDH1/2野生型星形细胞瘤的157例患者(平均年龄58岁(20-87岁),女性占36.9%)。

主要发现

  • 主要组织学为间变性星形细胞瘤WHO 3级(78.3%),其次为弥漫性星形细胞瘤WHO 2级(21.7%)。
  • 全切除占37.6%,次全切除占28.7%,活检占33.8%。
  • 中位无进展生存期12.5个月和中位总生存期27.0个月在WHO分级间无差异。
  • 全切除和次全切除较活检显著延长无进展生存期(P<0.01)和总生存期(P<0.001)。
  • 按Stupp方案治疗与单独化疗或放疗相比,未与更长的总生存期或无进展生存期相关;EGFR扩增(P=0.014)和TERT启动子突变(P=0.042)与总生存期缩短相关;MGMT启动子甲基化对治疗反应无影响。

临床怎么用

  • 作者认为年龄、切除程度和强EGFR表达是最重要的治疗相关预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Isocitrate dehydrogenase (IDH)1/2 wildtype (wt) astrocytomas formerly classified as WHO grade II or III have significantly shorter PFS and OS than IDH mutated WHO grade 2 and 3 gliomas leading to a classification as CNS WHO grade 4. It is the aim of this study to evaluate differences in the treatment-related clinical course of these tumors as they are largely unknown. METHODS: Patients undergoing surgery (between 2016-2019 in six neurosurgical departments) for a histologically diagnosed WHO grade 2-3 IDH1/2-wt astrocytoma were retrospectively reviewed to assess progression free survival (PFS), overall survival (OS), and prognostic factors. RESULTS: This multi-center study included 157 patients (mean age 58 years (20-87 years); with 36.9% females). The predominant histology was anaplastic astrocytoma WHO grade 3 (78.3%), followed by diffuse astrocytoma WHO grade 2 (21.7%). Gross total resection (GTR) was achieved in 37.6%, subtotal resection (STR) in 28.7%, and biopsy was performed in 33.8%. The median PFS (12.5 months) and OS (27.0 months) did not differ between WHO grades. Both, GTR and STR significantly increased PFS (P < 0.01) and OS (P < 0.001) compared to biopsy. Treatment according to Stupp protocol was not associated with longer OS or PFS compared to chemotherapy or radiotherapy alone. EGFR amplification (P = 0.014) and TERT-promotor mutation (P = 0.042) were associated with shortened OS. MGMT-promoter methylation had no influence on treatment response. CONCLUSIONS: WHO grade 2 and 3 IDH1/2 wt astrocytomas, treated according to the same treatment protocols, have a similar OS. Age, extent of resection, and strong EGFR expression were the most important treatment related prognostic factors.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Keric N, Krenzlin H, Kalasauskas D, et al. Treatment outcome of IDH1/2 wildtype CNS WHO grade 4 glioma histologically diagnosed as WHO grade II or III astrocytomas. J Neurooncol. 2024. PMID: 38326661. doi:10.1007/s11060-024-04585-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。